CA3115587C - Process for the preparation of a pde4 inhibitor - Google Patents

Process for the preparation of a pde4 inhibitor

Info

Publication number
CA3115587C
CA3115587C CA3115587A CA3115587A CA3115587C CA 3115587 C CA3115587 C CA 3115587C CA 3115587 A CA3115587 A CA 3115587A CA 3115587 A CA3115587 A CA 3115587A CA 3115587 C CA3115587 C CA 3115587C
Authority
CA
Canada
Prior art keywords
formula
compound
crystal form
date received
date recue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3115587A
Other languages
English (en)
French (fr)
Other versions
CA3115587A1 (en
Inventor
Alessandro Falchi
Emilio Lutero
Emanuele Ferrari
Fausto Pivetti
Rocco BUSSOLATI
Edoardo Mariani
Orsola VECCHI
Erhard Bappert
Caterina VENTRICI
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49385193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3115587(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Priority to CA3115587A priority Critical patent/CA3115587C/en
Publication of CA3115587A1 publication Critical patent/CA3115587A1/en
Application granted granted Critical
Publication of CA3115587C publication Critical patent/CA3115587C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3115587A 2013-10-22 2014-10-17 Process for the preparation of a pde4 inhibitor Active CA3115587C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3115587A CA3115587C (en) 2013-10-22 2014-10-17 Process for the preparation of a pde4 inhibitor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13189784 2013-10-22
EP13189784.5 2013-10-22
CA2928242A CA2928242C (en) 2013-10-22 2014-10-17 Process for the preparation of a pde4 inhibitor
CA3115587A CA3115587C (en) 2013-10-22 2014-10-17 Process for the preparation of a pde4 inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2928242A Division CA2928242C (en) 2013-10-22 2014-10-17 Process for the preparation of a pde4 inhibitor

Publications (2)

Publication Number Publication Date
CA3115587A1 CA3115587A1 (en) 2015-04-30
CA3115587C true CA3115587C (en) 2026-01-06

Family

ID=49385193

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3115587A Active CA3115587C (en) 2013-10-22 2014-10-17 Process for the preparation of a pde4 inhibitor
CA3115570A Active CA3115570C (en) 2013-10-22 2014-10-17 Process for the preparation of a pde4 inhibitor
CA2928242A Active CA2928242C (en) 2013-10-22 2014-10-17 Process for the preparation of a pde4 inhibitor

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3115570A Active CA3115570C (en) 2013-10-22 2014-10-17 Process for the preparation of a pde4 inhibitor
CA2928242A Active CA2928242C (en) 2013-10-22 2014-10-17 Process for the preparation of a pde4 inhibitor

Country Status (29)

Country Link
US (7) US9434691B2 (https=)
EP (5) EP3060551B1 (https=)
JP (5) JP6458957B2 (https=)
KR (3) KR102240865B1 (https=)
CN (5) CN110256338A (https=)
AR (4) AR098128A1 (https=)
AU (1) AU2014339136C1 (https=)
BR (1) BR112016008161B1 (https=)
CA (3) CA3115587C (https=)
CY (1) CY1123811T1 (https=)
DK (3) DK3293176T3 (https=)
ES (3) ES2980505T3 (https=)
FI (1) FI3587400T3 (https=)
HR (3) HRP20240783T1 (https=)
HU (3) HUE067681T2 (https=)
IL (4) IL285532B2 (https=)
LT (2) LT3587400T (https=)
MX (4) MX370104B (https=)
MY (1) MY182559A (https=)
PH (3) PH12020500162B1 (https=)
PL (3) PL3587400T3 (https=)
PT (3) PT3587400T (https=)
RS (2) RS61558B1 (https=)
RU (1) RU2682660C9 (https=)
SG (4) SG10201903575UA (https=)
SI (3) SI3060551T1 (https=)
TW (3) TWI685486B (https=)
UA (2) UA121853C2 (https=)
WO (1) WO2015059050A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3246016T3 (da) 2010-08-03 2025-05-19 Chiesi Farm Spa Tørpulverformulering indeholdende en fosfodiesterasehæmmer
SI3060551T1 (sl) * 2013-10-22 2019-11-29 Chiesi Farm Spa Postopek za pripravo inhibitorja PDE4
WO2018017713A1 (en) * 2016-07-20 2018-01-25 Allergan, Inc. Methods, compositions, and compounds for treatment of dermatological and ocular conditions
JP7361584B2 (ja) * 2018-12-19 2023-10-16 高砂香料工業株式会社 アミドの還元によるアミンの製造方法
JP6780763B2 (ja) 2018-12-25 2020-11-04 トヨタ自動車株式会社 内燃機関の制御装置
US11149615B2 (en) 2018-12-25 2021-10-19 Toyota Jidosha Kabushiki Kaisha Control device for internal combustion engine
CN111808029A (zh) * 2020-08-31 2020-10-23 兰晟生物医药(苏州)有限公司 一种pde4抑制剂氯比普兰的制备方法
EP4452223A1 (en) 2021-12-21 2024-10-30 Chiesi Farmaceutici S.p.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
AU2023262106A1 (en) 2022-04-27 2024-12-05 Chiesi Farmaceutici S.P.A. Crystal form of a pde4 inhibitor
CN115304542B (zh) * 2022-07-18 2024-02-02 湖南华纳大药厂手性药物有限公司 一种3-羟基吡啶的合成工艺
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
KR20250069950A (ko) 2022-09-22 2025-05-20 키에시 파르마슈티시 엣스. 피. 에이. 포스포다이에스테라제-4 억제제의 투여를 위한 캡슐 흡입기
PE20251716A1 (es) 2022-09-22 2025-07-07 Chiesi Farm Spa Inhalador de capsula para la administracion de un inhibidor de fosfodiesterasa-4
EP4590272A1 (en) 2022-09-22 2025-07-30 Chiesi Farmaceutici S.p.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
KR102925863B1 (ko) 2023-11-27 2026-02-09 국립한국해양대학교산학협력단 복수의 학습모델을 이용한 이미지 기반의 강도 추정 장치 및 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
AU2001239442A1 (en) * 2000-03-30 2001-10-15 Chirotech Technology Limited Ruthenium-diphosphine complexes and their use as catalysts
WO2005026095A1 (en) 2003-09-12 2005-03-24 Ranbaxy Laboratories Limited Process for the preparation of roflumilast
PL1740593T3 (pl) 2004-04-19 2016-09-30 Sposoby wytwarzania wodorosiarczanu klopidogrelu w formie polimorficznej I
ATE459618T1 (de) * 2004-04-29 2010-03-15 Aventis Pharma Inc 3-piperidinylisochroman-5-ole als dopaminagonisten
KR20070079278A (ko) 2006-02-01 2007-08-06 삼성전자주식회사 수신자 제한 시스템을 이용하는 디지털 멀티미디어시스템에서 수신기의 채널 전환 시간 단축 장치 및 방법
DE602007012105D1 (de) * 2006-07-14 2011-03-03 Chiesi Farma Spa Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
EP2125736B1 (en) * 2006-12-22 2011-03-30 Leo Pharma A/S Substituted acetophenones useful as pde4 inhibitors
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
US20100015430A1 (en) 2008-07-16 2010-01-21 Outlast Technologies, Inc. Heat Regulating Article With Moisture Enhanced Temperature Control
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
ES2528957T3 (es) 2010-06-14 2015-02-13 Chiesi Farmaceutici S.P.A. Forma cristalina del cloruro de glicopirronio
DK3246016T3 (da) * 2010-08-03 2025-05-19 Chiesi Farm Spa Tørpulverformulering indeholdende en fosfodiesterasehæmmer
CA2807406C (en) * 2010-08-03 2018-12-11 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
CN103827088B (zh) * 2011-09-26 2017-10-13 奇斯药制品公司 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物
WO2013087749A1 (en) * 2011-12-16 2013-06-20 Chiesi Farmaceutici S.P.A. Potentiation induced by pde4 inhibitors in the treatment of leukemia
KR102192739B1 (ko) * 2012-12-05 2020-12-18 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
CN103304408B (zh) * 2013-06-05 2016-10-05 威海迪素制药有限公司 罗氟司特中间体3-环丙甲氧基-4-二氟甲氧基苯甲酸的制备
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
SI3060551T1 (sl) * 2013-10-22 2019-11-29 Chiesi Farm Spa Postopek za pripravo inhibitorja PDE4
KR101591785B1 (ko) 2013-12-24 2016-02-04 주식회사 투게더 데이터 입력 장치, 이를 이용한 데이터 전송 시스템 및 방법
BR112020012972A2 (pt) * 2017-12-28 2020-11-24 Chiesi Farmaceutici S.P.A. uso de derivados de álcool 1-fenil-2-piridinil alquílico para tratar fibrose cística
EP4452223A1 (en) * 2021-12-21 2024-10-30 Chiesi Farmaceutici S.p.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Also Published As

Publication number Publication date
CN105658629B (zh) 2019-07-16
PL3060551T3 (pl) 2020-03-31
ES2759514T3 (es) 2020-05-11
US10323003B2 (en) 2019-06-18
HK1223926A1 (zh) 2017-08-11
ES2980505T3 (es) 2024-10-01
KR20210021416A (ko) 2021-02-25
CA3115570C (en) 2024-01-30
JP7345581B2 (ja) 2023-09-15
AR118124A2 (es) 2021-09-22
IL285528A (en) 2021-09-30
EP3060551A1 (en) 2016-08-31
TW201605804A (zh) 2016-02-16
MY182559A (en) 2021-01-25
EP3060551B1 (en) 2019-09-18
JP7051970B2 (ja) 2022-04-11
IL245220A (en) 2017-06-29
IL252834A0 (en) 2017-08-31
KR102287598B1 (ko) 2021-08-11
PL3587400T3 (pl) 2024-07-01
AR122183A2 (es) 2022-08-24
RU2016115246A3 (https=) 2018-06-27
SI3293176T1 (sl) 2021-04-30
IL285528B2 (en) 2025-09-01
EP3293176A1 (en) 2018-03-14
US20190345108A1 (en) 2019-11-14
PH12016500737A1 (en) 2016-05-30
PT3060551T (pt) 2019-12-09
FI3587400T3 (fi) 2024-06-20
KR20160072127A (ko) 2016-06-22
US9890122B2 (en) 2018-02-13
KR20210021415A (ko) 2021-02-25
RU2682660C2 (ru) 2019-03-20
TWI685486B (zh) 2020-02-21
PL3293176T3 (pl) 2021-06-28
AR122182A2 (es) 2022-08-24
DK3293176T3 (da) 2021-02-15
US11352327B2 (en) 2022-06-07
CN114621139A (zh) 2022-06-14
HUE046637T2 (hu) 2020-03-30
EP3587400B1 (en) 2024-03-20
TWI651305B (zh) 2019-02-21
UA121853C2 (uk) 2020-08-10
PT3587400T (pt) 2024-06-05
US10759761B2 (en) 2020-09-01
MX370104B (es) 2019-12-02
KR102287596B1 (ko) 2021-08-11
PH12016500737B1 (en) 2022-03-23
CA3115570A1 (en) 2015-04-30
PH12020500162A1 (en) 2021-08-02
US20150111931A1 (en) 2015-04-23
UA127453C2 (uk) 2023-08-30
US20180118686A1 (en) 2018-05-03
WO2015059050A1 (en) 2015-04-30
EP4059921A1 (en) 2022-09-21
US9434691B2 (en) 2016-09-06
SG10201912852YA (en) 2020-02-27
BR112016008161B1 (pt) 2022-11-29
IL285532A (en) 2021-09-30
HRP20210336T1 (hr) 2021-04-16
HUE067681T2 (hu) 2024-11-28
JP2019038813A (ja) 2019-03-14
CN114621139B (zh) 2025-06-20
SG11201603130TA (en) 2016-05-30
HRP20240783T1 (hr) 2024-09-27
DK3060551T3 (da) 2019-10-28
BR112016008161A2 (https=) 2017-08-01
CA3115587A1 (en) 2015-04-30
EP3293176B1 (en) 2020-12-02
RU2016115246A (ru) 2017-11-27
IL285532B2 (en) 2024-03-01
AR098128A1 (es) 2016-05-04
JP2021011494A (ja) 2021-02-04
MX2022000030A (es) 2022-07-19
LT3587400T (lt) 2024-04-25
SG10201903575UA (en) 2019-05-30
IL285528B1 (en) 2025-05-01
CN120136784A (zh) 2025-06-13
RS65452B1 (sr) 2024-05-31
LT3293176T (lt) 2021-03-25
EP3587400A3 (en) 2020-03-25
MX389002B (es) 2025-03-20
JP7534346B2 (ja) 2024-08-14
EP3587400A2 (en) 2020-01-01
KR102240865B9 (ko) 2021-12-13
CA2928242A1 (en) 2015-04-30
SI3060551T1 (sl) 2019-11-29
HUE053112T2 (hu) 2021-06-28
CN120607463A (zh) 2025-09-09
KR102240865B1 (ko) 2021-04-16
TWI720803B (zh) 2021-03-01
JP2017505752A (ja) 2017-02-23
SI3587400T1 (sl) 2024-05-31
MX2016004834A (es) 2016-07-19
DK3587400T3 (da) 2024-04-02
CN105658629A (zh) 2016-06-08
IL252834B (en) 2021-09-30
IL285532B1 (en) 2023-11-01
TW201904945A (zh) 2019-02-01
JP6458957B2 (ja) 2019-01-30
JP2022068321A (ja) 2022-05-09
US20240166605A1 (en) 2024-05-23
RS61558B1 (sr) 2021-04-29
PH12021550257A1 (en) 2023-01-23
PT3293176T (pt) 2021-03-03
SG10202112587RA (en) 2021-12-30
CA2928242C (en) 2022-03-15
US11981639B2 (en) 2024-05-14
US20160326117A1 (en) 2016-11-10
US20210040040A1 (en) 2021-02-11
US20220348545A1 (en) 2022-11-03
MX2019014408A (es) 2020-01-27
AU2014339136B2 (en) 2018-05-31
CY1123811T1 (el) 2022-05-27
PH12020500162B1 (en) 2024-06-14
AU2014339136C1 (en) 2019-10-31
ES2857629T3 (es) 2021-09-29
JP2022071008A (ja) 2022-05-13
IL245220A0 (en) 2016-06-30
EP3798209A1 (en) 2021-03-31
CN110256338A (zh) 2019-09-20
TW202021952A (zh) 2020-06-16
RU2682660C9 (ru) 2019-06-21
MX2022000036A (es) 2022-07-19
HRP20192152T1 (hr) 2020-02-21

Similar Documents

Publication Publication Date Title
CA3115587C (en) Process for the preparation of a pde4 inhibitor
AU2014339136A1 (en) Process for the preparation of a PDE4 inhibitor
HK40068745A (en) Process for the preparation of a pde4 inhibitor
HK40012263A (en) Process for the preparation of a pde4 inhibitor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210419

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241011

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241011

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241011

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250325

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250325

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20250722

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250801

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250801

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251010

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251010

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20260105

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20260106